FATE News and Press, Fate Therapeutics Inc. From 02/26/24

SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...

2024-02-16 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived c...

SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders...

2024-01-29 13:21:09 ET Gainers: Neximmune ( NEXI ) +94% . Palisade Bio PALI +83% . Rail Vision Ltd ( RVSN ) +68% . Revelation Biosciences ( REVB ) +54% . Mercurity Fintech Holding MFH +34% . J-Long Group Ltd JL +29% . Intelli...

2024-01-26 09:13:32 ET Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last ar...

iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase 1 Study is Being Conducted in Collaboration with Ono Pharmaceutical SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Fate Thera...

2023-12-18 09:45:07 ET CSX Corp. (CSX) CSX is trading UP for the last 5 days, and it at trading at $34.33 with volume of 2,174,565 and a one day change of $0.33 (0.96%). CSX Corp. has a 52-week low of 27.60 and a 52-week high of $34.38. The business's 50-day moving average price is ...

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders...

2023-12-12 16:51:29 ET Gainers: Innovative International Acquis ( IOAC ) +24% . EF Hutton Acquisition Corporation  ( EFHT ) +5% . Denali Therapeutics  ( DNLI ) +4% . SLM Corporation ( SLM ) +4% . BioCryst Pharmaceuticals ( BC...